Impact of vancomycin pharmacokinetic properties on treatment outcome in Staphylococcus aureus infectio
Not Applicable
Recruiting
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0001082
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 230
Inclusion Criteria
Among all adult (>=18years) patients with Staphylococcus aureus bacteremia at participating hospital during the study period
1) Patients who agree to the gathering clinical information about S. aureus bacteremia by means of an informed consent.
2) Patients who fulfill the criteria of a waiver: Patients who died or transferred within 2 weeks after the onset of bacteremia, an informed consent was waived by institutional review board.
Vancomycin-treated patient with methicillin-resistant Staphylococcus aureus bacteremia who fulfill the above criteria.
Exclusion Criteria
Patienst who do not agree the participation in this study, except for patients who fulfill the criteria of a waiver of informed consent.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment failure: (1) death within 30 days, or (2) persisent MSSA bacteremia for more than 7 days, or (3) recurrence of MSSA bacteremia within 30 days after completion of antibiotic treatment) ;MRSA bacteremia-associated mortality
- Secondary Outcome Measures
Name Time Method Analysis of risk factors for treatment failure ;Replacement of antibiotics due to adverse effect of vancomycin;Analysis of relationship between vancomycin MIC and treatment outcome;Analysis of relationship between archievement of target trough level and treatment outcome